Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2011 4
2012 2
2013 4
2014 1
2016 1
2017 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC. Beukers W, et al. Among authors: lorente ja. J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31. J Urol. 2017. PMID: 28049011 Clinical Trial.
PURPOSE: Patients with nonmuscle invasive bladder cancer are followed with frequent cystoscopies. In this study FGFR3, TERT and OTX1 were investigated as a diagnostic urinary marker combination during followup of patients with primary nonmuscle invasive bladder
PURPOSE: Patients with nonmuscle invasive bladder cancer are followed with frequent cystoscopies. In this study FGFR3, TERT and OTX1 …
Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV, Amaral AF, Armitage EG, Lorente JA, Algaba F, Carrilho E, Márquez M, García A, Malats N, Barbas C. Alberice JV, et al. Among authors: lorente ja. J Chromatogr A. 2013 Nov 29;1318:163-70. doi: 10.1016/j.chroma.2013.10.002. Epub 2013 Oct 4. J Chromatogr A. 2013. PMID: 24139504
Identified metabolites have been analysed in terms of disease characteristics (tumour stage and recurrence) and have provided an insight into bladder cancer progression. ...Some, for example histidine, phenylalanine, tyrosine and tryptophan have been previously linked with …
Identified metabolites have been analysed in terms of disease characteristics (tumour stage and recurrence) and have provided an insight int …
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S. Juanpere N, et al. Among authors: lorente ja. Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12. Hum Pathol. 2012. PMID: 22417847
Different members of the phosphoinositide 3 kinase--serine threonine protein kinase (PI3K-AKT) pathway are altered in bladder cancer. ...Other genes different from FGFR3 may be related with the pERK activation in bladder tumors....
Different members of the phosphoinositide 3 kinase--serine threonine protein kinase (PI3K-AKT) pathway are altered in bladder cancer. …
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX. Allory Y, et al. Among authors: lorente ja. Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7. Eur Urol. 2014. PMID: 24018021 Clinical Trial.
OBJECTIVES: To investigate TERT mutation frequency, spectrum, association with expression and clinical outcome, and potential for detection of recurrences in urine in patients with urothelial bladder cancer (UBC). ...In urine, TERT mutations had 90% specificity in subjects …
OBJECTIVES: To investigate TERT mutation frequency, spectrum, association with expression and clinical outcome, and potential for detection …
Clinical-pathological differences and smoking habit depending on gender in a cohort of patients with transitional cell carcinoma of the bladder: retrospective study.
Lorente JA, Bielsa O, Rijo E, Cortadellas R, Nohales G, Francés A, Juanpere N, Lloreta J, Arango O. Lorente JA, et al. Arch Esp Urol. 2011 Jun;64(5):427-33. Arch Esp Urol. 2011. PMID: 21705815 English, Spanish.
OBJECTIVES: The increased incidence of transitional cell carcinoma (TCC) of the bladder in men is known, generally attributed to greater exposure to the effect carcinogenic products. ...The aim of this study is to analyze whether there are gender-related differences in gra …
OBJECTIVES: The increased incidence of transitional cell carcinoma (TCC) of the bladder in men is known, generally attributed to grea …
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
Balbás-Martínez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Márquez M, Vazquez M, Lapi E, Castro-Giner F, Beltran S, Bayés M, Carrato A, Cigudosa JC, Domínguez O, Gut M, Herranz J, Juanpere N, Kogevinas M, Langa X, López-Knowles E, Lorente JA, Lloreta J, Pisano DG, Richart L, Rico D, Salgado RN, Tardón A, Chanock S, Heath S, Valencia A, Losada A, Gut I, Malats N, Real FX. Balbás-Martínez C, et al. Among authors: lorente ja. Nat Genet. 2013 Dec;45(12):1464-9. doi: 10.1038/ng.2799. Epub 2013 Oct 13. Nat Genet. 2013. PMID: 24121791 Free PMC article.
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological and genetic levels. Tumor invasiveness (T) and grade (G) are the main factors associated with outcome and determine patient management. ...Loss of expression was often observed in chromosomally …
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological and genetic levels. Tumor invasiveness (T) and grade ( …
[Cystitis and ketamine associated bladder dysfunction].
García-Larrosa A, Castillo C, Ventura M, Lorente JA, Bielsa O, Arango O. García-Larrosa A, et al. Among authors: lorente ja. Actas Urol Esp. 2012 Jan;36(1):60-4. doi: 10.1016/j.acuro.2011.06.020. Epub 2011 Sep 28. Actas Urol Esp. 2012. PMID: 21955556 Spanish.
OBJECTIVES: To analyze the prevalence of lower urinary tract symptoms (LUTS) in recreational ketamine users and evaluate its relationship with the consumption pattern. ...
OBJECTIVES: To analyze the prevalence of lower urinary tract symptoms (LUTS) in recreational ketamine users and evaluate its relation …
FGFR3 mutations in prostate cancer: association with low-grade tumors.
Hernández S, de Muga S, Agell L, Juanpere N, Esgueva R, Lorente JA, Mojal S, Serrano S, Lloreta J. Hernández S, et al. Among authors: lorente ja. Mod Pathol. 2009 Jun;22(6):848-56. doi: 10.1038/modpathol.2009.46. Epub 2009 Apr 17. Mod Pathol. 2009. PMID: 19377444 Free article.
This gene does not seem to be central to the pathogenesis of prostate cancer, but it is significantly associated with a subgroup of low-grade prostate tumors, and with the finding of other tumors, mainly arising in bladder and skin....
This gene does not seem to be central to the pathogenesis of prostate cancer, but it is significantly associated with a subgroup of low-grad …
ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
Balbás-Martínez C, Rodríguez-Pinilla M, Casanova A, Domínguez O, Pisano DG, Gómez G, Lloreta J, Lorente JA, Malats N, Real FX. Balbás-Martínez C, et al. Among authors: lorente ja. PLoS One. 2013 May 1;8(5):e62483. doi: 10.1371/journal.pone.0062483. Print 2013. PLoS One. 2013. PMID: 23650517 Free PMC article.
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological, genetic, and epigenetic levels. Exome sequencing has identified ARID1A as a novel tumor suppressor gene coding for a chromatin remodeling protein that is mutated in UBC. ...The independent find …
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological, genetic, and epigenetic levels. Exome sequencing has …
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
Agell L, Hernández S, Salido M, de Muga S, Juanpere N, Arumí-Uria M, Menendez S, Lorenzo M, Lorente JA, Serrano S, Lloreta J. Agell L, et al. Among authors: lorente ja. Mod Pathol. 2011 Mar;24(3):443-52. doi: 10.1038/modpathol.2010.208. Epub 2010 Nov 26. Mod Pathol. 2011. PMID: 21113138 Free article.
A total of 102 prostate tumors, 79 from prostate cancer alone (group G1) and 23 from bladder and prostate cancer patients (G2), are the subject of this study. In 20 of these 23, the bladder tumors were also analyzed. PIK3CA, KRAS, BRAF and AKT1 mutations were analyz …
A total of 102 prostate tumors, 79 from prostate cancer alone (group G1) and 23 from bladder and prostate cancer patients (G2), are t …
12 results
Jump to page
Feedback